Bioventus (BVS) Price & Analysis

Compare

186 Followers

BVS Stock Chart & Stats

$7.00

-$0.12(-1.26%)

At close: Jan 08 4:00 PM EST

$7.00

-$0.12(-1.26%)

Day’s Range― - ―

52-Week Range$5.81 - $11.75

Previous CloseN/A

Volume116.12K

Average Volume (3M)351.12K

Market Cap

$595.07M

Enterprise Value$798.62M

Total Cash (Recent Filing)$42.16M

Total Debt (Recent Filing)$322.58M

Price to Earnings (P/E)64.0

Beta0.88

Next Earnings

Mar 17, 2026

EPS Estimate

0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.15

Shares Outstanding66,976,480

10 Day Avg. Volume248,718

30 Day Avg. Volume351,121

Financial Highlights & Ratios

PEG Ratio0.26

Price to Book (P/B)4.64

Price to Sales (P/S)1.20

P/FCF Ratio18.16

Enterprise Value/Market Cap1.34

Enterprise Value/Revenue1.42

Enterprise Value/Gross Profit2.10

Enterprise Value/Ebitda8.90

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceCash flow from operations materially increased 71% to nearly $26M, indicating strong financial performance.

Growth StrategyBioventus has set in place levers to drive both short and long-term growth and expects a back-half improvement in its growth rate.

Innovation In Pain TreatmentsThe company is focusing on emerging areas of pain treatments with the potential for significant growth, particularly in PRP and PNS segments.

Bears Say

Bioventus News

Bioventus Appoints Ajay Dhankhar as New Director

Bioventus ( ($BVS) ) has shared an update. On November 14, 2025, Bioventus Inc. appointed Ajay Dhankhar, PhD,...

25d ago

BVS

Bioventus Reports Strong Q3 2025 Financial Performance

Bioventus, Inc. ( ($BVS) ) has released its Q3 earnings. Here is a breakdown of the information Bioventus,...

1M ago

BVS

Bioventus, Inc. Reports Strong Q3 Earnings Growth

Bioventus, Inc. (($BVS)) has held its Q3 earnings call. Read on for the main highlights of the call....

1M ago

BVS

Bioventus reports Q3 EPS 15c vs 5c last year

Reports Q3 revenue $138.7M, consensus $138.19M. “Momentum continued to build across our portfolio as our team delivered an...

1M ago

BVS

Bioventus sees FY25 EPS 64c-68c

Sees FY25 revenue $560M-$570M, consensus $566.83M Published first on TheFly – the ultimate source for real-time, market-moving breaking...

1M ago

BVS

BVS Earnings this Week: How Will it Perform?

Bioventus, Inc. (BVS) is scheduled to report 3rd quarter earnings on 11/04/2025, before the market opens. Regarding Q3...

1M ago

BVS

Bioventus: Strategic Initiatives and Growth Prospects Drive Buy Rating

Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on Bioventus yesterday and set a price target of...

4M ago

BVS

Bioventus Earnings Call: Strong Growth and Resilience

Bioventus, Inc. (($BVS)) has held its Q2 earnings call. Read on for the main highlights of the call....

4M ago

BVS

Bioventus Inc. Reports Q2 2025 Financial Results

Bioventus, Inc. ( ($BVS) ) has released its Q2 earnings. Here is a breakdown of the information Bioventus,...

4M ago

BVS

Bioventus reports Q2 EPS 21c, consensus 20c

Reports Q2 revenue $147.66M, consensus $145.86M. “Our team delivered another strong quarter, and we are well positioned to...

4M ago

BVS

Bioventus sees FY25 EPS 64c-68c, consensus 66c

Sees FY25 revenue $560M-$570M, consensus $565.41M Published first on TheFly – the ultimate source for real-time, market-moving breaking...

4M ago

BVS

Bioventus Secures $400 Million Credit Agreement

Bioventus ( ($BVS) ) just unveiled an announcement. On July 31, 2025, Bioventus LLC entered into a $400...

4M ago

BVS

Bioventus enters $400M senior secured credit agreement

Bioventus (BVS) entered into a $400M Senior Secured Credit Agreement consisting of a $300M term loan facility and...

4M ago

BVS

Bioventus Gains FDA Clearance for Key PNS Products

Bioventus ( ($BVS) ) just unveiled an announcement. On July 30, 2025, Bioventus Inc. announced that it received...

4M ago

BVS

BVS FAQ

What was Bioventus, Inc.’s price range in the past 12 months?

Bioventus, Inc. lowest stock price was $5.81 and its highest was $11.75 in the past 12 months.

What is Bioventus, Inc.’s market cap?

Bioventus, Inc.’s market cap is $595.07M.

When is Bioventus, Inc.’s upcoming earnings report date?

Bioventus, Inc.’s upcoming earnings report date is Mar 17, 2026 which is in 95 days.

How were Bioventus, Inc.’s earnings last quarter?

Bioventus, Inc. released its earnings results on Nov 04, 2025. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.105 by $0.045.

Is Bioventus, Inc. overvalued?

According to Wall Street analysts Bioventus, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioventus, Inc. pay dividends?

Bioventus, Inc. does not currently pay dividends.

What is Bioventus, Inc.’s EPS estimate?

Bioventus, Inc.’s EPS estimate is 0.2.

How many shares outstanding does Bioventus, Inc. have?

Bioventus, Inc. has 66,976,480 shares outstanding.

What happened to Bioventus, Inc.’s price movement after its last earnings report?

Bioventus, Inc. reported an EPS of $0.15 in its last earnings report, beating expectations of $0.105. Following the earnings report the stock price went up 15.091%.

Which hedge fund is a major shareholder of Bioventus, Inc.?

Currently, no hedge funds are holding shares in BVS

Bioventus Stock Smart Score

Neutral

Fundamentals

Return on Equity

4.97%

Trailing 12-Months

Asset Growth

-8.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bioventus, Inc.

Bioventus (BVS) is a global leader in the development and commercialization of innovative therapies for musculoskeletal health. The company operates primarily in the orthopedic and pain management sectors, focusing on solutions that enhance healing and improve patient outcomes. Bioventus' core products include its proprietary ultrasound therapy systems, biologic products for joint health, and a range of other advanced medical devices aimed at treating conditions related to bone and soft tissue.

Bioventus (BVS) Earnings & Revenues

Historic Earnings Reports

BVS Company Deck

BVS Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant organic growth, profitability improvements, and strategic advancements in new markets, alongside effective cash and debt management. The main challenge was the impact of prior divestitures and foreign exchange losses.View all BVS earnings summaries

BVS Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","16":"$16","7.75":"$7.75","10.5":"$10.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,7.75,10.5,13.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.55,7.199999999999999,7.85,8.5,9.149999999999999,9.799999999999999,10.45,11.099999999999998,11.75,12.399999999999999,13.049999999999999,13.7,14.349999999999998,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.55,6.046153846153846,5.542307692307692,5.038461538461538,4.5346153846153845,4.030769230769231,3.526923076923077,3.023076923076923,2.519230769230769,2.0153846153846153,1.5115384615384615,1.0076923076923077,0.5038461538461538,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.55,7.123076923076923,7.696153846153846,8.269230769230768,8.842307692307692,9.415384615384614,9.988461538461538,10.561538461538461,11.134615384615383,11.707692307692307,12.28076923076923,12.853846153846153,13.426923076923076,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.05,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.79,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >